SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-2001

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Likely several years away. The drug is still in Phase 1 dose expansion with no registrational trial initiated. If Phase 1 data support advancement, Phase 2/3 trials would need to be completed before any regulatory filing, likely 2028-2030 at the earliest.
Why 2/10
ABBV-2001 is a Phase 1 asset with no scheduled PDUFA, pivotal readout, or other hard binary catalyst in the next ~12 months. It is a small part of AbbVie's massive pipeline, so even data readouts would have negligible impact on the stock.
Actionable Insight NEUTRAL

Watch for Phase 1 dose-expansion data from the TRIgnite-1 study (NCT05862012), which could come at a medical meeting in 2027. Positive data would support advancement to Phase 2/3, but ABBV-2001 is a small pipeline component for AbbVie, so even strong readouts are unlikely to move the stock materially. The more relevant near-term catalyst for AbbVie's multiple myeloma franchise is the etentamig (ABBV-383) BLA, submitted to the FDA on October 27, 2026.

Price Chart

Loading chart...

Executive Summary

ABBV-2001 (ISB 2001) is a first-in-class trispecific T-cell engager targeting CD38, BCMA, and CD3, being developed by AbbVie for relapsed/refractory multiple myeloma. AbbVie licensed the drug from Ichnos Glenmark Innovation in July 2025 for $700M upfront (up to $1.925B total). It is currently in Phase 1 dose expansion (TRIgnite-1 study) and has shown promising early data: a 79% overall response rate and 30% complete response rate across active dose levels in heavily pretreated patients, including activity after prior BCMA-targeted therapy. The drug has received FDA Orphan Drug and Fast Track designations. However, it remains an early-stage asset years from potential approval, and for AbbVie (a ~$295B market cap company), it is a very small part of a large pipeline.

How It Works

ABBV-2001 is a trispecific antibody (a type of engineered immune protein) that grabs T-cells (the immune system's killer cells) with one arm and simultaneously latches onto two different targets on myeloma cancer cells (BCMA and CD38). This brings the T-cells close to the cancer cells so they can destroy them. By targeting two cancer-cell markers at once, the drug aims to work even when cancer cells have stopped expressing one of the targets, potentially overcoming resistance to existing bispecific antibody therapies.

Trial Status

ABBV-2001 is being studied in the TRIgnite-1 Phase 1 first-in-human trial (NCT05862012), which completed dose escalation (Part 1) and is now in Part 2 dose expansion to confirm safety and select the recommended Phase 2 dose. AbbVie is also running a separate Phase 1 combination study (M25-059) testing ABBV-2001 alongside its BCMA bispecific etentamig (ABBV-383). Phase 1 dose-escalation data presented at ASCO 2025 (24 patients) showed a 79% ORR and 30% CR/sCR rate with no dose-limiting toxicities. Updated data at IMS 2026 showed a 64% rate of VGPR or better with low rates of CRS and ICANS.

The Two-Sided Case

▲ Bull Case4
ABBV-2001 is a first-in-class trispecific T-cell engager targeting both BCMA and CD38 simultaneously, which could overcome resistance mechanisms that limit existing bispecific antibodies. Phase 1 data showed a 79% ORR and 30% CR/sCR rate in heavily pretreated patients, including 73% ORR in patients who had already failed prior BCMA-targeted therapies.
The drug has shown a favorable safety profile with no dose-limiting toxicities and mostly mild CRS, which could support outpatient administration and a broad label if later trials succeed.
AbbVie has deep expertise in multiple myeloma (etentamig BLA just filed) and strong commercial infrastructure, giving ABBV-2001 a clear development and launch pathway if Phase 2/3 data are positive.
FDA has granted both Orphan Drug and Fast Track designations, providing regulatory advantages and potential accelerated pathways.
▼ Bear Case4
ABBV-2001 is still in Phase 1 dose expansion with no pivotal trial started, meaning regulatory approval is likely years away (if it ever comes).
The multiple myeloma treatment landscape is crowded with approved bispecific antibodies from J&J (Tecvayli), Pfizer (Elrexfio), and Regeneron (Lynozyfic), plus AbbVie's own etentamig (ABBV-383) BLA was just submitted. ABBV-2001 will need to differentiate on efficacy, safety, or convenience to carve out a role.
AbbVie paid $700M upfront and up to $1.925B total in milestones for this asset, a significant outlay for a Phase 1 drug that has not yet demonstrated a registrational path.
For AbbVie (a ~$295B market cap company), ABBV-2001 is a tiny pipeline component. Even positive data would have negligible impact on the stock price.

Upcoming Catalysts

  • Phase 1 dose-expansion data from TRIgnite-1 study (likely at a medical meeting in 2027)
  • Potential initiation of Phase 2/3 registrational study if dose expansion confirms the recommended dose and safety profile

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 12

Hover a chip for the title
1 news.abbvie.com2 fiercebiotech.com3 prnewswire.com4 ascopubs.org5 insights.citeline.com6 news.abbvie.com7 iginnovate.com8 iginnovate.b-cdn.net9 news.abbvie.com10 abbvieclinicaltrials.com11 ashpublications.org12 pryzm.ozmosi.com